The eastern cooperative oncology group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

✍ Scribed by Geoffrey Falkson; Rebecca S. Gelman; Douglass C. Tormey; Frank J. Cummings; Paul P. Carbone; Hendré C. Falkson

• Publisher: John Wiley and Sons
• Year: 1985
• Tongue: English
• Weight: 497 KB
• Volume: 56
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19850715)56:2<219::aid-cncr2820560202>3.0.co;2-q

✦ Synopsis

Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed. Twenty-three percent had complete remission; 39% had partial remission; 28% had no change; and 3% had disease progression. Of those patients in whom receptors were known, response rates were 65% for estrogen (ERkreceptor positive and 70% for ER-negative patients. The median duration of response was 11.4 months. The median survival time from the start of CAF was 20.2 months. The response rate, time to treatment failure (TIT), and median survival time were superior in the premenopausal women. These differences ceased, however, to be statistically significant in logistic models. Factors significantly associated with longer I T F and longer survival were as follows: one or two organs with metastases ('ITF, P < O.OOO1; survival, P < O.OOO1); dominant site other than soft tissue ('ITF, P < 0.0001; survival, P = 0.05); and an initial good performance status (ITF, P = 0.007; survival, P = 0.02). Patients with ER-positive disease had a significantly longer median survival time ( P = 0.003).

Cuncer 56:219-224, 1985.

ROSPECTIVELY RANDOMIZED ChiCal trials showed P that cyclophosphamide, Adriamycin (doxorubicin)

and 5-fluorouracil (CAF) was superior to cyclophosphamide. methotrexate and 5-fluorouracil (CMF) for achieving responses in women with advanced breast cancer. A response rate of 82% was achieved with CAF; the response rate for CMF was 62%. There were no significant differences in toxicities encountered in this study.' Median survival time was 24 months for CAFtreated patients and I7 months for CMF-treated patients.

The 5-year survival was 10% for CAF-treated patients and 5% for CMF-treated patients.' In a subsequent study